Title: Modelling and molecular dynamics simulation of novel anticancer ligand for restructuring mutant P53 into wild type

Authors: Ashik Chhetri; Moloy Roy; Aditi Gangopadhyay; Achintya Saha; Puja Mishra; Amit Kumar Halder; Souvik Basak

Addresses: Dr. B.C. Roy College of Pharmacy & Allied Health Sciences, Durgapur-713206, WB, India ' Dr. B.C. Roy College of Pharmacy & Allied Health Sciences, Durgapur-713206, WB, India ' Department of Chemical Technology, University of Calcutta, Kolkata-700009, WB, India ' Department of Chemical Technology, University of Calcutta, Kolkata-700009, WB, India ' Dr. B.C. Roy College of Pharmacy & Allied Health Sciences, Durgapur-713206, WB, India ' Dr. B.C. Roy College of Pharmacy & Allied Health Sciences, Durgapur-713206, WB, India ' Dr. B.C. Roy College of Pharmacy & Allied Health Sciences, Durgapur-713206, WB, India

Abstract: Mutant p53 is one key factor of cancer or cellular oncogenesis as mutant P53 loses its functions due to the unfolding of its loops, losing its dynamics, DNA-protein interaction, and thus losing its function. Thus, one of the key strategies for developing anti-cancer drugs may be to design leads that can revert mutant P53 to wild type P53. In this regard, we have designed two nitrogen-based heterocyclic ligands that are computationally revealed to revert mutant P53 to wild type. In addition, molecular dynamics simulation revealed a stable complex of the ligands with mutant P53, conformational flexibility of the ligand with the binding cleft and the loop, and structural reversal of the mutant P53 into a protein that mimics wild type P53. We claim this may be the promising lead of broad-spectrum anticancer drugs since it has the potential for functional reversal of mutant P53 in carcinogenic cells.

Keywords: mutant P53; LEA3D; genetic algorithm; molecular dynamics; binding cleft.

DOI: 10.1504/IJCBDD.2022.126990

International Journal of Computational Biology and Drug Design, 2022 Vol.15 No.2, pp.77 - 95

Accepted: 01 Jun 2022
Published online: 16 Nov 2022 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article